Вероятные патогенетические варианты спорадического рака яичников
https://doi.org/10.17650/1994-4098-2012-0-3-4-112-119
Аннотация
В статье рассматривается вероятная патогенетическая модель рака яичника, особенности его гистогенеза, роль овуляции, хронического воспаления и стволовых клеток. Представлена схема развития 2 вариантов рака яичников, а также возможные пути профилактики.
Ключевые слова
рак яичников,
патогенез,
овуляция,
поверхностный эпителий,
гетеротопии,
хроническое воспаление,
стволовая клетка
Об авторе
Л. А. Ашрафян
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России, Москва
Россия
Россия
Список литературы
1. Аксель Е.М. Статистика злокачественных новообразований женской половой сферы. Онкогинекология 2012;1:18−23.
2. Глазунов М.Ф. Опухоли яичников. М.: Медгиз, 1954. С. 324.
3. Auersperg N., Wong A.S., Choi K.C. et al. Ovarian surface epithelium: biology, endocrinology and pathology. Endocr Rev 2001;22:225−8.
4. Noara H. Developmental vpatterning in the wrong context: The paradox of epithelial ovarian cancers. Cell Cycle 2005;4:1033−5.
5. Walthard M.Z. Aetiologieder Ovarialadenoma. Ztschr Geburtsh Gynak 1903;49:233−329.
6. Keller Th. L’activite normale et pathologique de l’epithelium germinatif de l’ovaire adalte. Gynecol Et Obstet 1928;17:10−39.
7. Максимов А.А. Die hystologishen Vorgange bei der Heilung von Eierstocksverletzungen und die Regenerationsfahigkeit des Eiertockgewebes. Virch Arch 1900; p. 160.
8. Дорохов И.И. Мезотелий париетальной брюшины человека и изменения его при некоторых заболеваниях. Л., 1951.
9. Schiffmann J., Steiner H. Knotchen und Cystchem an der Tube. Zbl Gynak 1926;50:258.
10. Muller J.H. Les nodules et Kystes paramalpighiennes a la surface de l’ovair, de la tromphe et du ligament large. Ann d’Anat Pathol 1934;11:438−98.
11. Danforth H. The cytologic relationship of the Walthard cell rest tо the Brenner tumor of the ovary and to the pseudomucinous cystadenoma. Am J Obst Gyn 1942;43:984.
12. Rubson S.M., Thill L.I. Epithelium-like Inclusions in the heart. Am J Path 1948;3:24.
13. Kowalski L.D., Kanbour A.I., Price F.V. et al. A case-matched molecular comparison of extraovar ian versus primary ovarian adenocarcinoma. Cancer 1997;79:1587−94.
14. Halperin R., Zehavi S., Hadas E. et al. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol 2001;20:341−5.
15. Halperin R., Zehavi S., Langer R. et al. Primary peritoneal serous papillary carcinoma: A new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 2001;11:403−8.
16. Chen L.M., Yamada S.D., Fu Y.S. et al. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 2003;13:749−55.
17. Lacy M.Q., Hartmann L.C., Keeney G.L. et al. C-erbB-2 and p53 expression in fallopian tube carcinoma. Cancer 1995;75:2891−6.
18. Pere H., Tapper J., Seppala M. et al. Genomic alterations in fallopian tube carcinoma: Comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis. Cancer Res 1998;58:4274−6.
19. Kindelberger D.W., Lee Y., Miron A. et al. Intraepithelial carcinoma of the fibria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161−9.
20. Whittemore A.S., Harris R., Itnyre J. et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US control studies. Am J Epidemiol 1992;136:1212−20.
21. Runnenbaum I.B., Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;123:73−9.
22. Cooper G.S., Schildkraut J.M., Whittemore A.S. et al. Pregnensy recency and risk of ovarian cancer. Cancer Caus Contr 1999;10:397−402.
23. NIH Consensus Development Conference Statement. Ovarian cancer: screening, treatment and follow-up. Gynecol Oncol 1994;55:4−14.
24. Riman T., Persont N.S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol Oxf 1998;49(6):695−707.
25. Gwinn M.L., Lee N.C., Rhodes P.H. et al. Pregnancy, breast feeding, and oral contra- ceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990;43:559−68.
26. Nanca P.C., Greenwald P., Chorost S. et al. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 1984;119:705−13.
27. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study 1968−2004. Br J Cancer 2006;95(3):385−9.
28. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774−86.
29. Brinton L.A., Lamb E.J., Moghissi K.S. et al. Ovarian cancer risk after the use of ovulation stimulating drugs. Obstet Gynecol 2004;103:1194−203.
30. Ness R.B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459−67.
31. Wang J., Luo F., Lu J.J. et al. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 2002;97:163−7.
32. Schiffenbauer Y.S., Meir G., Maoz M. et al. Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol Oncol 2002;84:296−302.
33. Rosenberg L., Palmer J.R., Zauber A.G. et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994;139:654−61.
34. Purdie D.M., Bain C.J., Siskind V. Hormon replacement therapy and the risk of epithelial ovarian cancer. Br J Cancer 1999; 81:559−64.
35. Gaspard U.J. Romus M.A., Gillain D. et al. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception 1983;27:577−90.
36. McNatty K.P., Smith D.M., Makris A. et al. The microenvironment of the human antral follicle: Inter- relationships among the steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte in vivo and in vitro. J Clin Endocrinol Metab 1979;49:851−60.
37. Tashiro H., Katabuchi H., Begum M. et al. Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and independent growth in human ovarian surface epithelial cell lines. Cancer Sci 2003;94:953−9.
38. Ji Q., Liu P.I., Chen P.K. et al. Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 2004;112:803−914.
39. Seeger H., Wallwiener D., Mueck A.O. Is there a protective role of progestogens on the proliferation of human ovarian cancer cells in the presence of growth factors? Eur J Gynaecol Oncol 2006;27:139−41.
40. Edmondson R.J., Monaghan J.M., Davies B.R. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 2002;86:879−85.
41. Altinoz M.A, Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxyge-naseinhibitions as likely mechanisms behind the acеtaminophen – and NSAID-prevention of the ovarian cancer. Neoplasma 2004;51:239−47.
42. Albini A., Tosseti F., Benelli R., Noonan D. Tumor inflammatory angiogenesis and its chemoprevation. Cancer Res 2005;65(23):10637−41.
43. Stecca B., Mas C., Altaba A. Interference with HH-GLI signaling inhibits cancer. Trends Mol Med 2005;11(5):199−203.
44. Shafer Z.T., Brugge J.S. IL-6 involvement in epitalial cancer. J Clin Invest 2004;117(12):3660−3.
Рецензия
Для цитирования:
Ашрафян Л.А. Вероятные патогенетические варианты спорадического рака яичников. Опухоли женской репродуктивной системы. 2012;(3-4):112-119. https://doi.org/10.17650/1994-4098-2012-0-3-4-112-119
For citation:
Ashrafyan L.A. Possible pathogenetic types of sporadical ovarian cancer. Tumors of female reproductive system. 2012;(3-4):112-119. (In Russ.) https://doi.org/10.17650/1994-4098-2012-0-3-4-112-119
Просмотров: 582
Послать статью по эл. почте 